Search
                    North Carolina Paid Clinical Trials
A listing of 2641  clinical trials  in North Carolina  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            2605 - 2616 of 2641
        
                North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
                                
            
            
        Recruiting
                            
            
                This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.             
        
        
    Gender:
                ALL
            Ages:
                Between 5 years and 17 years
            Trial Updated:
                10/05/2023
            
            Locations: Bausch Health Site 010, Greenville, North Carolina         
        
        
            Conditions: Ulcerative Colitis
        
            
        
    
                
                                    Biomarker Development for Muscular Dystrophies
                                
            
            
        Recruiting
                            
            
                Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using t...  Read More             
        
        
    Gender:
                ALL
            Ages:
                5 years and above
            Trial Updated:
                10/04/2023
            
            Locations: Wake Forest University, Winston-Salem, North Carolina         
        
        
            Conditions: Myotonic Dystrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy
        
            
        
    
                
                                    Estrogen Variability and Irritability During the Menopause Transition
                                
            
            
        Recruiting
                            
            
                Women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. About 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. Among the perimenopausal women with affective impairment, most report irritability, not "depression," is their primary source of impairment and distress. The purpose of this research is to determine the neurophysiolog...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 45 years and 59 years
            Trial Updated:
                10/02/2023
            
            Locations: Carolina Crossing B, Suite 1, Chapel Hill, North Carolina         
        
        
            Conditions: Menopause, Irritable Mood
        
            
        
    
                
                                    Hearing Screener Study
                                
            
            
        Recruiting
                            
            
                The objective is to compare the Linus Health Hearing Screener (LHHS) to established hearing screening methods performed by a hearing specialist. We will perform an in-office speech hearing test and compare the thresholds with those measured from the iPad at a distance of 1ft with a sound pressure level (SPL) (dBA) meter             
        
        
    Gender:
                ALL
            Ages:
                55 years and above
            Trial Updated:
                09/27/2023
            
            Locations: Crossover Mangement, Wake Forest, North Carolina         
        
        
            Conditions: Hearing Screener
        
            
        
    
                
                                    Advancing Vaccine Equity Through Understanding Vaccine Hesitancy, Barriers, and Trust
                                
            
            
        Recruiting
                            
            
                In the proposed study, the investigators will conduct qualitative interviews and focus groups with Black, Hispanic, and medically underserved communities, living in the rural south and will provide a quantitative survey (mixed methods) to identify reasons for vaccine hesitancy, including any structural barriers experienced by this population. The investigators will assess what vaccination messaging was received by trusted individuals and how this messaging may have impacted vaccination behavior....  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/25/2023
            
            Locations: East Carolina University, Greenville, North Carolina         
        
        
            Conditions: Vaccine Hesitancy, Structural Barriers, Vaccine Trust
        
            
        
    
                
                                    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are:
* safety and tolerability of the gene therapy; and
* whether the gene therapy helps the heart ventricles relax during filling. Participants will undergo a one-time infusion of the gene therapy in the cardiac catheterization laboratory and then be followed for safety and effect...  Read More             
        
        
    Gender:
                ALL
            Ages:
                50 years and above
            Trial Updated:
                09/23/2023
            
            Locations: Duke University, Durham, North Carolina         
        
        
            Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
        
            
        
    
                
                                    The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
                                
            
            
        Recruiting
                            
            
                The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo.
The secondary objective of this study is to compare the safety of Bonjesta in pregnant adolescents aged 12 to 17 years with placebo.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 12 years and 17 years
            Trial Updated:
                09/08/2023
            
            Locations: Unified Women's Clinical Research, Winston-Salem, North Carolina         
        
        
            Conditions: Morning Sickness
        
            
        
    
                
                                    Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers
                                
            
            
        Recruiting
                            
            
                The purpose of this clinical evaluation is to collect and compare outcomes data from patients with UT 1A diabetic foot ulcers treated with 510K FDA cleared, commercially available self-assembling peptide, AC5®Advanced Wound System, as compared to an advanced standard of care. Patient outcomes will be compared at the end of the study.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/07/2023
            
            Locations: Dr. Christopher Gauland, Greenville, North Carolina         
        
        
            Conditions: Non-healing Wound, Diabetic Foot Ulcer
        
            
        
    
                
                                    Study of 3D Scanning for Adolescent Scoliosis
                                
            
            
        Recruiting
                            
            
                The investigators aim to validate three-dimensional topographical scanning technology as a tool for evaluation of scoliosis. Through the incorporation of 3D topographical technology in the measurement of deformity, the investigators hope to validate a novel approach to quantify deformity progression and provide an accessible alternative to traditional radiographic workup.             
        
        
    Gender:
                ALL
            Ages:
                Between 10 years and 18 years
            Trial Updated:
                09/06/2023
            
            Locations: Duke University, Durham, North Carolina         
        
        
            Conditions: Scoliosis
        
            
        
    
                
                                    A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
                                
            
            
        Recruiting
                            
            
                This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                09/01/2023
            
            Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina         
        
        
            Conditions: Ulcerative Colitis
        
            
        
    
                
                                    AltaValve Early Feasibility Study Protocol
                                
            
            
        Recruiting
                            
            
                Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/31/2023
            
            Locations: Atrium Health, Charlotte, North Carolina         
        
        
            Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
        
            
        
    
                
                                    A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
                                
            
            
        Recruiting
                            
            
                This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/03/2023
            
            Locations: Duke University, Durham, North Carolina         
        
        
            Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
        
            
        
    